Review demonstrates robust efficacy of novel antibody constructs across diverse hematologic and solid tumors, highlighting strategies to overcome resistance and toxicity.
Key Points
To review the evolving clinical landscape, therapeutic mechanisms, resistance pathways, and future translational directions of antibody-drug conjugates and bispecific antibodies in oncology.
Synthesized recent clinical trial evidence evaluating antibody-drug conjugates and bispecific antibodies across solid tumors and hematologic malignancies.
Evaluated target antigens (such as HER2, TROP2, CLDN18.2, CD20, BCMA, and DLL3), resistance mechanisms, toxicity profiles, and combinatory therapeutic sequencing.
Antibody-drug conjugates such as trastuzumab deruxtecan broadened treatable populations in HER2-low breast cancer and demonstrated notable central nervous system activity.
T-cell-engaging bispecific antibodies achieved deep, durable clinical responses across refractory hematologic malignancies (targeting CD20, BCMA, and GPRC5D) and solid tumors (targeting DLL3 and EGFR-MET).
Key clinical obstacles remain, including unique toxicities, antigen escape, T-cell exhaustion, and a lack of validated predictive biomarkers to guide optimal sequencing.